Changing the view of cancer
Elephas is committed to helping pharmaceutical and biotechnology researchers accelerate immunotherapy drug development with a breakthrough approach for assessing response to investigational agents.
Powered by our Cybrid™ platform, our technology suite is the only solution based on live tumor fragments (LTF)™ with the native tumor architecture and immune cells intact.
With Cybrid™ we can generate an array of outputs, including secretome profiling, cellular markers, transcriptome analysis, and advanced 3D imaging using multiphoton microscopy and optical coherence tomography.*
* For Research Use Only. Not for use in diagnostic procedures.